British judge upholds one UK patent on Pfizer's cholesterol drug Lipitor, invalidates another


Wednesday, October 12th 2005, 10:44 am
By: News On 6


LONDON (AP) _ A British judge upheld a United Kingdom patent covering the active ingredient in Pfizer Inc.'s blockbuster cholesterol drug Lipitor on Wednesday, but ruled that a second patent was invalid. Pfizer's shares rose more than 2.5 percent.

Judge Nicholas Pumfrey ruled in the case which was brought by Indian pharmaceutical company Ranbaxy Laboratories Ltd., which wants to release a generic version of the drug in Britain and was was challenging both patents, and by Britian's Arrow Generics Ltd., which was challenging the second patent that was ruled invalid.

Pfizer, the world's biggest drugmaker, said the decision upholding the exclusivity of the patent covering atorvastatin, the active ingredient in Lipitor, until November 2011, was an important victory for scientists.

``This court decision is consistent with the fundamental principle that patent laws exist to support and encourage medical innovators, not undermine them,'' Pfizer chairman and CEO Hank McKinnell said in a statement.

Lipitor is the world's best selling drug, with revenues of $10.86 billion last year. Pfizer said 7 percent of Lipitor sales are generated in the United Kingdom

New York-based Pfizer said it would appeal the decision on the second patent, which expires in July 2010 and covers the calcium salt of atorvastatin.

Ranbaxy vice president Charles Caprariello said the company would appeal the ruling which upheld the main patent.

Unless the decision about the main patent is overturned, Ranbaxy can't introduce a patent in the United Kingdom until November 2011, Pfizer said.

But Pfizer faces a far more significant threat to Lipitor. Ranbaxy has brought a suit against two Lipitor patents in the United States, where $6.6 billion of the drug's sales are generated. A ruling is anticipated by the end of the year.

The U.S. Food and Drug Administration last month approved widening the pool of people who can take the popular cholesterol drug to reduce the risk of stroke and heart attack to many diabetics who have risk factors for heart disease.

Prudential Equity Group Inc. analyst Timothy Anderson wrote that Wall Street is divided on how the U.S. decision on Lipitor's patents will go, but that his legal consultants expect Pfizer to win on the critical active ingredient patent. He noted that because of the differences in U.S. and U.K. law, it was hard to say whether the U.K. verdict foreshadows a favorable U.S. decision.